IDEXX Laboratories, Inc. $IDXX Holdings Increased by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,662 shares of the company’s stock after buying an additional 1,904 shares during the quarter. Motley Fool Asset Management LLC’s holdings in IDEXX Laboratories were worth $5,860,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. EverSource Wealth Advisors LLC raised its position in shares of IDEXX Laboratories by 2.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after buying an additional 15 shares in the last quarter. Harbour Investments Inc. raised its position in shares of IDEXX Laboratories by 13.3% during the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after buying an additional 16 shares in the last quarter. CWA Asset Management Group LLC raised its position in shares of IDEXX Laboratories by 3.5% during the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock worth $344,000 after buying an additional 17 shares in the last quarter. Stratos Wealth Partners LTD. raised its position in shares of IDEXX Laboratories by 1.7% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock worth $683,000 after buying an additional 18 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC raised its position in shares of IDEXX Laboratories by 11.5% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock worth $111,000 after buying an additional 18 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. UBS Group dropped their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $578.89 on Wednesday. The firm’s 50 day moving average is $563.22 and its 200-day moving average is $630.28. The stock has a market capitalization of $45.66 billion, a P/E ratio of 42.63, a P/E/G ratio of 3.07 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.